TScan Therapeutics (TCRX) Interest Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Interest Expenses data on file, last reported at $689000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses rose 1.47% year-over-year to $689000.0 in Q1 2026; TTM through Mar 2026 was $3.1 million, a 7.47% decrease from a year earlier, with the FY2025 full-year figure at $84.0 million, up 757.07% from the prior year.
• Interest Expenses for Q1 2026 stood at $689000.0, down from $1.0 million in the prior quarter.
• Over the last five years, Interest Expenses for TCRX reached as high as $6.5 million in Q4 2023 and fell as low as $201000.0 in Q3 2022.
• Historically, Interest Expenses has averaged $1.3 million across 5 years, with a median of $956000.0 in 2023.
• Across the five-year window, Interest Expenses tumbled 97.87% in 2022 and jumped 388.56% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $1.8 million in 2022, then jumped by 260.92% to $6.5 million in 2023, then slumped by 87.93% to $784000.0 in 2024, then soared by 33.16% to $1.0 million in 2025, then tumbled by 34.0% to $689000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $689000.0 in Q1 2026, $1.0 million in Q4 2025, and $699000.0 in Q3 2025.